Foundational guide
Tesamorelin Dosage Chart: Provenance You Can Actually Trace
One of the few compounds covered here whose quantities trace to an approved label rather than a rodent study. The chain is checkable, and it terminates at a narrow indication.
Most dosage figures examined on this site cannot be traced to a primary source that applies to a person. They originate in rodent studies, where quantities are expressed per kilogram of animal body weight, and the conversion to a human figure is the step nobody can justify.
Tesamorelin is the exception worth studying, because its chain of provenance is complete and every link in it can be checked from a public record.
The chain, link by link
| Link | What exists | Verifiable where |
|---|---|---|
| Trial programme | Roughly 24 registered studies | ClinicalTrials.gov |
| Regulatory review | BLA 022505, Theratechnologies | Drugs@FDA |
| Marketed product | EGRIFTA, latterly EGRIFTA SV, prescription powder | Drugs@FDA, DailyMed |
| Indication | Excess abdominal fat in HIV-associated lipodystrophy | Approved label |
| Stated limitation | Long-term cardiovascular safety not established | Approved label |
Every row is checkable in under a minute, and none of it depends on taking a vendor's word for anything. That is a materially different situation from the compounds on this site whose entire dosing discourse rests on a mouse study and an unstated conversion.
The field that decides what the numbers mean
A complete provenance chain is necessary but not sufficient, because the authorisation attaches to an indication rather than to a molecule. Here the indication is a single line: reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.
A tesamorelin dosage chart that carries that indication alongside its quantities is reporting a tier one source accurately. A chart that carries the quantities alone has silently changed the claim, because the reader supplies their own population and the table does not object.
One further distinction the chart cannot make for you
The approved product and research-chemical material sold under the same compound name are not the same object analytically. The first carries a labelled mass a manufacturer is accountable for and a regulator reviewed. The second carries a seller's assertion, which is why every concentration calculation performed on it inherits an unquantified error at the numerator.
A dosage chart describes quantities. Whether the vial in front of you contains what its label says is a separate question, and no chart answers it.
Frequently asked questions
- Can the dosage figures for tesamorelin be traced to a primary source?
- Yes, which is unusual for this site. They trace to an approved FDA label under BLA 022505, rather than to an animal study requiring a species conversion.
- What evidence tier does the compound reach?
- Tier one. A completed trial programme, roughly 24 registered studies, a regulatory review and a marketed prescription product.
- Does tier one status transfer to every use?
- No. The tier attaches to the approved indication, which is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Outside that pairing the evidence tier drops sharply.
- Is research-chemical tesamorelin the same product?
- No. The approved product carries a labelled mass a manufacturer is accountable for. Research-chemical material carries a seller's claim, which is a different kind of statement.
- Does the label state any gap in its own evidence?
- Yes. It states that long-term cardiovascular safety has not been established, and directs prescribers to weigh risk and benefit where visceral adipose tissue has not reduced.
Limitations of the evidence
This page evaluates provenance and prints no administration guidance. Tesamorelin is approved by the FDA as EGRIFTA, latterly EGRIFTA SV, under BLA 022505 held by Theratechnologies, for one indication: reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. The label states that long-term cardiovascular safety has not been established. Quantities authorised for that population and that endpoint carry no authorisation for any other use, and material sold as a research chemical is not the approved product and carries no verified labelled mass. Nothing here describes or recommends human use.